Compounded GLP-1 RA market reveals widespread B vitamin co-formulation and supplier licensing deficiencies post-shortage.
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for weight loss, but high costs, insurance barriers, and supply shortages have fueled a robust market for compounded versions. This unregulated market raises concerns about product quality and patient safety. A systematic assessment of this market, particularly after the end of major semaglutide and tirzepatide shortages, is crucial to understand the landscape of available products and supplier practices.
Study Design
A cross-sectional secret shopper study was conducted from August to October 2025 in West Virginia and Oklahoma, states selected for high obesity rates and specific insurance mixes. Researchers identified 75 brick-and-mortar weight-loss clinics and medical spas advertising GLP-1 RAs for weight loss. The study characterized available compounded GLP-1 RA products, assessed aspects of patient care and monitoring, and identified source pharmacies, including their licensing status and any objectionable conditions or disciplinary actions.
Results
The analysis of 75 identified businesses revealed significant trends in compounded GLP-1 RA offerings.
56.0% of the businesses reported offering compounded GLP-1 RA products combined with B vitamins, suggesting a common co-formulation strategy. Additionally, 7 (9.3%) businesses offered oral compounded GLP-1 RA formulations. A total of 23 compounding facilities were identified as suppliers for these businesses. Concerningly, 4 of 21 (19.0%) of these facilities were not licensed to perform sterile compounding, a critical requirement for injectable medications. Furthermore, 1 (4.3%) facility had received multiple US Food and Drug Administration (FDA) warning letters since 2023, indicating significant regulatory non-compliance. These findings highlight potential quality control and safety issues within the compounded GLP-1 RA market.
Key Findings
- 56.0% of compounded GLP-1 RA products were offered with B vitamins.
- 9.3% of businesses offered oral compounded GLP-1 RA formulations.
- 19.0% of identified compounding suppliers were not licensed for sterile compounding.
- 4.3% of suppliers had received multiple FDA warning letters since 2023.
- 75 weight-loss clinics and medical spas were identified offering compounded GLP-1 RAs.
Why It Matters
This study reveals critical insights into the unregulated compounded GLP-1 RA market, highlighting potential risks for consumers. Patients considering compounded GLP-1 RAs should verify the licensing and regulatory compliance of their compounding pharmacy. The widespread co-formulation with B vitamins, while not inherently harmful, may not be medically necessary and could indicate a marketing tactic rather than a therapeutic enhancement. The significant proportion of unlicensed sterile compounding facilities and those with FDA warnings underscores an urgent need for enhanced regulatory oversight and enforcement to protect public health. This data informs both consumers and regulators about the current state of this rapidly expanding market.
compounded glp-1 ra
glp-1 ra
weight loss
market analysis
regulatory compliance
patient safety